TrialTracker_MD said:Denials are usually procedural rather than clinical, and the order that works reflects that.
TrialTracker_MD said:...regarding the discontinuation data for cost and coverage...
I want to reframe the discontinuation narrative. We don't say "insulin fails because blood sugar rises when you stop it." We don't say "antihypertensives fail because BP goes up without them."
Why do we apply different logic to anti-obesity medications? The answer is stigma. We still, unconsciously, believe obesity is about willpower rather than biology. The discontinuation data actually PROVES it's a chronic biological condition requiring ongoing treatment.
This reframing isn't semantic — it has implications for insurance coverage, treatment duration, and patient expectations.
A narrower follow-up, since the general answer is now clear:
What would you measure differently if you were starting again?
VendorMark said:TrialTracker_MD said: ...regarding the discontinuation data for cost and coverage...
My insurance denied my PA related to cost and coverage. Has anyone successfully appealed? I'm considering going compounded instead.
PeptideDetective — Independent Peptide Analytics
Community-driven peptide testing and vendor rating platform. Transparent results. Unbiased analysis. Trusted by thousands.
View ResultsReporting back.
Update: approved on the third attempt after a peer-to-peer. Nothing about my case changed; only who was doing the talking.
julia.endo said:My insurance denied my PA related to cost and coverage.
Financial impact of cost and coverage weight loss beyond medication cost:
- Groceries: SAVED $267/month (eating less)
- Restaurants: SAVED $197/month (fewer meals out)
- Alcohol: SAVED $147/month (stopped drinking)
- Life insurance: Premium REDUCED by $37/month (lower BMI)
- Copays: SAVED $57/month (fewer BP/cholesterol meds)
Net impact after medication cost: approximately BREAKING EVEN. The medication pays for itself through reduced food spending and healthcare costs. This surprised me.